Get in Touch
Talk to a Scientific Specialist to to learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical application.
Learn HowCREATE TRANSFORMATIVE MEDICINES
Translate biology insights into genetic medicines
Latest News
August 11, 2021 — Precision NanoSystems sets time and place to open new Genetic Medicine GMP Biomanufacturing Centre in Vancouver, BC Learn More
We are pleased to announce that Precision NanoSystems (PNI) is joining the Danaher Life Sciences platform.
Together with Pall Corporation and Cytiva, we will further enable development of transformative medicines that improve the lives of patients. PNI, Cytiva, and Pall Corporation offer complementary portfolios from equipment and consumables through to fully
flexible manufacturing solutions, designed for the manufacturing of genetic medicine-based therapies from discovery to commercial production. For more information, see the full press release.
-
Disease TargetBiology insights can identify target gene(s) driving disease
Genetic Medicine Toolkit
-
Choose RNA/DNA to silence, express, or edit target gene(s) -
Lipid nanoparticles (LNP) protect & deliver RNA/DNA to target cells -
Microfluidics manufactures genetic medicines seamlessly from discovery to clinic
-
Leverage world-leading expertise in genetic medicine development
mRNA & DNA-based vaccines Prophylactic & therapeutic
Infectious Disease & Oncology
Population-based to individualized
Infectious Disease & Oncology
Population-based to individualized
siRNA, mRNA, DNA, CRISPR
Silence, express, or edit genes
Focus on rare disease
Population-based to individualized
Silence, express, or edit genes
Focus on rare disease
Population-based to individualized
siRNA, mRNA, DNA, CRISPR
Immune cells including T-Cells
Focus on oncology
Autologous & allogeneic
Immune cells including T-Cells
Focus on oncology
Autologous & allogeneic
Get Started
Learn how Precision NanoSystems can help accelerate development of genetic medicines.
Flexible Access to the Toolkit and Workflows
Use the NanoAssemblr Manufacturing platform and the GenVoy Delivery platform from the Genetic Medicine Toolkit in your laboratories. Our global team is available for onsite support.
Precision has an experienced team dedicated to development of genetic medicines on behalf of our partners. Our team uses the Genetic Medicine Toolkit and Workflows to develop vaccines, gene therapies and cell therapies from idea to commercial product.
-
The scalability and reproducibility of PNI’s NanoAssemblr platform allowed us to move into GMP manufacturing with greater control over the process and increased precision in the final product compared to our previous macromixing process, allowing acceleration of our time to commercialization.
David Evans, PhD
Chief Scientific Officer
Sirnaomics -
PNI is globally renowned for their NanoAssembr suite of products that enable high quality, consistent nanoparticle formation and seamless scale up from the laboratory to GMP manufacturing for the clinic. Using their GMP System will let us meet the challenge of producing our pan-coronavirus DNA vacci...
Read More
John Lewis, PhD
Chief Executive Officer
Entos -
As an Evonik affiliate specialized in liposomal drug delivery systems, we are pleased to offer our clients access to the NanoAssemblr GMP System, which will aid in the translation of drug candidates to clinical testing and ideally to commercial use.
Don Enns
Vice President
Evonik Vancouver Laboratories -
We look forward to working with Precision NanoSystems to support research efforts around the discovery of novel sLNPs that we believe have the potential to significantly improve and broaden biodistribution. sLNPs represent an exciting and innovative approach in Alnylam’s advancement of proprietary L...
Read More
Kenneth Koblan, PhD
Chief Scientific Officer
Alnylam -
The ease, reproducibility, and the robustness of PNI’s products is amazing compared to what we previously had used, and that’s been a real enabling factor for Guide as we’ve continued to grow over the last year and a half.
Corey Sago, PhD
Chief Technology Officer
Guide Therapeutics -
We are excited about this promising collaboration and hope that it will propel our work forward as the ncRNA Core Facility focuses on the non-coding RNA portions of the genome for [the] discovery of novel biomarkers and targets for therapeutics from human disease tissue and clinical trial specimens.
Frank Slack, PhD
Director of Initiative for RNA
Harvard Medical School -
The NanoAssemblr Blaze from Precision NanoSystems is very good for the rapid scale-up of nanoparticle-based formulations. We were able to seamlessly transition our formulation developed on the NanoAssemblr Benchtop to the Blaze instrument and make large scale batches on the Blaze. The Blaze instrume...
Read More
Muthusamy Jayaraman, PhD
Senior Director, Head of Non-Viral Delivery
CRISPR Therapeutics -
eTheRNA used the NanoAssemblr® NxGen technology because we could perform precise tuning of the size of our nanoparticles to target the optimal immunogenicity in vivo.
Bernard Sagaert
Vice President of Manufacturing
eTheRNA -
In terms of ease of operation it almost doesn’t compare. The Ignite is really, really smooth. It genuinely takes about half the time to make the same subset of particles when we’re using the same machines (NABT and Ignite). It really does feel like the benchtop came out, it was out for a few years, ...
Read More
Jay Wroe
Sr. Research Associate
Guide Therapeutics
Sign Up and Stay Informed
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.